Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Horvath

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Journal of Telemedicine and Telecare|October 18, 2021
Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemicAndrew O Parsonson, Peter Grimison, Michael Boyer, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 17, 2017
Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancerTejaswi Kandula, Michelle A Farrar, Matthew C Kiernan, et al.
Therapeutic Advances in Medical Oncology|December 18, 2024
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapyRhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2018
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup>Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen BlockadeLouise Emmett, Charlotte Yin, Megan Crumbaker, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2021
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumoursSunit Sarkar, Ben Tran, Lisa Horvath, et al.
JCO Clinical Cancer Informatics|July 25, 2023
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate CancerShikai Fang, Shandian Zhe, Hui-Ming Lin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 8, 2017
Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi surveyJ Matt McCrary, David Goldstein, Frances Boyle, et al.
Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.
European Urology|February 6, 2018
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate CancerSarah Q To, Edmond M Kwan, Heidi C Fettke, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal of Telemedicine and Telecare|October 18, 2021
Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemicAndrew O Parsonson, Peter Grimison, Michael Boyer, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 17, 2017
Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancerTejaswi Kandula, Michelle A Farrar, Matthew C Kiernan, et al.
Therapeutic Advances in Medical Oncology|December 18, 2024
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapyRhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2018
Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup>Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen BlockadeLouise Emmett, Charlotte Yin, Megan Crumbaker, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2021
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumoursSunit Sarkar, Ben Tran, Lisa Horvath, et al.
JCO Clinical Cancer Informatics|July 25, 2023
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate CancerShikai Fang, Shandian Zhe, Hui-Ming Lin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 8, 2017
Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi surveyJ Matt McCrary, David Goldstein, Frances Boyle, et al.
Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.
European Urology|February 6, 2018
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate CancerSarah Q To, Edmond M Kwan, Heidi C Fettke, et al.
Pageof 5